MedPal AI (MPAL) has entered the at-home blood testing market with the launch of its MedPal weight loss blood test, marking an expansion into diagnostics and adding a third revenue stream.
The UK digital health and artificial intelligence company said the clinically validated kit is designed for users of GLP-1 medications such as Mounjaro and Wegovy, who require regular blood monitoring. It forms the first product in a wider diagnostics range planned for rollout during 2026.
Samples are collected at home using the Tasso+ device and analysed by a UKAS-accredited laboratory to ISO 15189 standards. Results are delivered within 48 hours directly into the MedPal app, where they are integrated with data from more than 100 wearable devices powered by Google’s Vertex AI to generate personalised health insights.
The launch complements MedPal’s existing AI wellness app and automated pharmacy operations at MedPal.clinic, creating a more integrated healthcare ecosystem spanning testing, diagnosis and treatment.
Initially, the kits will be offered exclusively to existing MedPal app users. However, a broader range of tests, including general health, men’s health, women’s hormonal health and wellness panels, is expected to roll out throughout 2026.
MedPal AI’s CEO & Founder Jason Drummond said: “Blood testing is the missing layer in consumer health. By combining wearables, blood biomarkers, AI insights and pharmacy fulfilment in one ecosystem, we can now take users seamlessly from insight to diagnosis to treatment.”.
View from Vox
This move strengthens MedPal’s position as an end-to-end digital health platform. By adding diagnostics, the company deepens user engagement while opening a new revenue stream, particularly as demand for GLP-1-related monitoring continues to grow.